Metabolic Peptides

Semaglutide (GLP-1 agonist)

Semaglutide is a long-acting GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It works by enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite through central GLP-1 receptor activation. Research and compounded protocols typically titrate from 0.25mg to 2.4mg weekly over 12+ weeks. HbA1c, fasting glucose, insulin, a full lipid panel, and liver enzymes are the standard biomarkers researchers track, with CRP sometimes added to monitor inflammatory changes.

Tirzepatide (GLP-1/GIP dual agonist)

Tirzepatide is a dual GLP-1/GIP receptor co-agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). By activating both incretin pathways, it produces larger reductions in HbA1c and body weight than GLP-1 monotherapy in head-to-head trials. Research and compounded protocols titrate from 2.5mg to 15mg weekly over 12+ weeks. HbA1c, fasting glucose, insulin, lipid panel, CRP, and body composition are the standard biomarkers researchers track. Our platform flags any dose escalations that skip titration steps, which is a common cause of GI side effects.

Mitochondrial ORF of the 12S rRNA Type-C

MOTS-C is a 16 amino acid peptide encoded within the mitochondrial 12S rRNA gene — one of the first mitochondrially-derived peptides identified. Research has focused on its activation of AMPK, improvements in insulin sensitivity, and downstream effects on glucose uptake, fatty acid oxidation, and exercise capacity. It is a newer class of peptide with less human data than GLP-1 agonists but substantial preclinical work. Research dosing is typically 5–10mg subcutaneously three times per week in 4–8 week cycles. Fasting glucose, insulin, HbA1c, lactate, and CRP are the standard response biomarkers.

Anti-Obesity Drug 9604

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) originally developed as an anti-obesity agent. It stimulates lipolysis and inhibits lipogenesis without the diabetogenic or growth-promoting effects of full HGH.

5-Amino-1-methylquinolinium

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied for its anti-obesity and metabolic effects. While not a peptide, it is commonly tracked in the peptide space due to its use in metabolic optimization protocols. It reduces fat cell size and promotes energy expenditure.

LY3437943

Retatrutide is a novel triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is in Phase 3 clinical trials for obesity and type 2 diabetes and has demonstrated the highest weight loss of any anti-obesity medication tested to date.

Victoza

Liraglutide is an FDA-approved GLP-1 receptor agonist used for type 2 diabetes (Victoza, 1.8 mg daily) and chronic weight management (Saxenda, 3.0 mg daily). It was the first GLP-1 agonist approved for obesity treatment and paved the way for semaglutide and tirzepatide.

Nicotinamide Adenine Dinucleotide

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in all living cells that plays a central role in cellular energy metabolism and redox reactions. Researchers study NAD+ for its involvement in mitochondrial function, DNA repair signaling via sirtuins and PARPs, and age-associated metabolic decline.

NN9838

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is under investigation as a weight management compound, both as a monotherapy and in combination with semaglutide (CagriSema), targeting amylin receptor-mediated satiety pathways.

FOXO4-D-Retro-Inverso

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.